PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.36%
Negative revenue growth while AVGO stands at 6.32%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-5.87%
Negative gross profit growth while AVGO is at 4.96%. Joel Greenblatt would examine cost competitiveness or demand decline.
-84.09%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-84.09%
Negative operating income growth while AVGO is at 1.00%. Joel Greenblatt would press for urgent turnaround measures.
-76.02%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-72.73%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-70.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.65%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-0.59%
Reduced diluted shares while AVGO is at 0.70%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-146.99%
Negative OCF growth while AVGO is at 9.32%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-206.14%
Negative FCF growth while AVGO is at 9.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
292.53%
10Y revenue/share CAGR at 50-75% of AVGO's 416.86%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
292.53%
5Y revenue/share CAGR above 1.5x AVGO's 134.28%. David Dodd would look for consistent product or market expansions fueling outperformance.
49.47%
3Y revenue/share CAGR at 75-90% of AVGO's 62.33%. Bill Ackman would expect new product strategies to close the gap.
-487.74%
Negative 10Y OCF/share CAGR while AVGO stands at 580.47%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-487.74%
Negative 5Y OCF/share CAGR while AVGO is at 92.77%. Joel Greenblatt would question the firm’s operational model or cost structure.
-142.40%
Negative 3Y OCF/share CAGR while AVGO stands at 39.51%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-48.71%
Negative 10Y net income/share CAGR while AVGO is at 869.72%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-48.71%
Negative 5Y net income/share CAGR while AVGO is 414.43%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-87.00%
Negative 3Y CAGR while AVGO is 16.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
791.18%
10Y equity/share CAGR in line with AVGO's 862.23%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
791.18%
5Y equity/share CAGR above 1.5x AVGO's 165.61%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
77.06%
Below 50% of AVGO's 201.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.01%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
13.71%
Inventory growth well above AVGO's 8.08%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.56%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
0.18%
Under 50% of AVGO's 5.15%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-39.85%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
9.86%
R&D growth drastically higher vs. AVGO's 13.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
7.77%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.